monitoring for the toxicities of these agents is undertaken. Assessing renal function in such studies is additionally important because impaired renal clearance of a drug can lead to toxicities in organs other than the kidney that are related to pre-treatment renal function (Gietema et al, 1995) .
In the case of GFR-based dosing of carboplatin, a clear relationship has been demonstrated between the rate of drug elimination (clearance -Cl) and overall systemic drug exposure, as quantified by the area under the plasma concentration time curve (AUC). This is implemented in the Calvert formula (Calvert et al, 1989) : Dose (mg) = AUC (mg ml -1 min -1 ) × (GFR (ml min -1 ) + 25).
In using this equation, dose adjustment is important in avoiding toxicity, which has been shown to be closely related to AUC (Egorin et al, 1984; Jodrell et al, 1992) . Using GFR to achieve a target AUC also ensures appropriate dosing for patients with higher-than-average GFR, who may otherwise receive inadequate treatment. Retrospective studies have shown that response rate in ovarian cancer (Jodrell et al, 1992) and relapse rate in testicular cancer (Childs et al, 1992) are related to the area under the curve to which patients are exposed. Despite the importance of measuring GFR, good methods of doing so are not readily available to many physicians treating cancer. The 51 Cr-EDTA clearance method (Chantler et al, 1969 ) is widely accepted as being accurate and reproducible and was used in many of the initial studies used to derive carboplatin dosing formulae in Europe. Other isotope-based methods, such as those using iodothalamate or DTPA have been shown to be equivalent (Perrone et al, 1990; Millward et al, 1996) . However, these methods are relatively costly and are not available in many parts of the world ( 51 Cr-EDTA is not licensed for this use in the USA). Alternative, more convenient, methods of estimating GFR have
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1 been in use for many years, usually based on a measure of serum creatinine (SCr), the age, size and sex of the patient (CockcroftGault (C&G) (Cockcroft and Gault, 1976) or Jelliffe (Jelliffe, 1973) ). Although approximately 20% of creatinine elimination is by tubular secretion (Perrone et al, 1992) , use of these methods to predict GFR is based on the assumption that creatinine is eliminated entirely by glomerular filtration. Also, variations in the assay methods for creatinine introduce another source of variability (Hartman, 1985) . These formulae were derived over 20 years ago using a 24-hour urinary creatinine clearance as the reference. Recent data on the plasma pharmacokinetics of carboplatin when the doses were calculated using the C&G formula as the estimate of GFR have shown that the AUCs obtained were significantly lower than those intended (Van Warmerdam et al, 1996; Ando et al, 1997) . A direct comparison with 51 Cr-EDTA clearance has shown that the C&G method overestimates GFR in patients with normal renal function (Calvert, 1997) . The use of weight as the index of body size can also lead to an overestimate of GFR in obese patients (Salazar and Corcoran, 1988) .
The measurement of creatinine clearance using a 24-hour urine collection has given satisfactory results for carboplatin dosing in some trials (Egorin et al, 1984) . However complete 24-hour urine collections are notoriously difficult to achieve and the accuracy of the result also depends on the method used for creatinine estimation (Perrone et al, 1992) .
We have developed a method to estimate GFR. In order to be widely applicable, it is based on the serum creatinine level and other readily obtainable covariates. The pharmacokinetics of 51 Cr-EDTA and its relationship to patient covariates were studied using a nonlinear hierarchical model in the computer program NONMEM. Two commonly used creatinine assays (kinetic Jaffe and enzymatic) were investigated to determine the consequences for GFR prediction. The formulae derived here provide better, assay-specific estimates for GFR, which are sufficiently precise and unbiased to be employed for carboplatin dose-optimization.
PATIENTS AND METHODS
A total of 102 patients, all performance status 0 or 1, undergoing treatment for cancer at the Northern Centre for Cancer Treatment, Newcastle General Hospital, UK were assessed. All patients gave informed consent and the study was approved by the local ethics committee. Prior to analysis, one patient was excluded because of acute renal failure, and another because of extremely high creatine kinase (2048 units l -1 ), secondary to chest wall invasion by tumour. 38 patients were randomly assigned to the validation set, which played no part in the development of the models. The remaining 62 patients were used to develop formulae for prediction of GFR. The following covariates were recorded: age, weight, height, sex, tumour type, weight change in the past month, presence of nephrectomy, presence of pelvic disease (defined as the presence of disease below the level of the renal pedicles), chemotherapy and concomitant medication, previous chemotherapy, liver function tests (bilirubin, alanine transaminase, alkaline phosphatase and albumin), other blood chemistry (urea, sodium, chlorine, potassium, creatinine and creatine kinase) and 51 Cr-EDTA pharmacokinetics. Blood samples for biochemistry were taken at the same time as the first baseline sample in the 51 Cr-EDTA estimation of renal function. A Hitachi 717 auto-analyser was used for the analysis of creatine kinase (CK-NAC activated kit, Boehringer-Mannheim) and serum creatinine by kinetic Jaffe (HiCo creatinine, Boehringer-Mannheim) and enzymatic (Creatinine PAP, Boehringer-Mannheim) methods. Cr-EDTA was administered as an intravenous bolus and plasma samples were withdrawn from the opposite arm at approximately 2, 3, 4 and 5 hours. Linear regression on the logarithmically transformed counts against time was used to estimate the elimination rate constant K, with volume of distribution V calculated by back extrapolation of this log-transformed data. Individual estimates of 51 Cr-EDTA clearance were calculated from the product KxV. This is the routine practice of the Medical Physics department and is a method widely employed for this purpose (Chantler et al, 1969) . These estimates of 51 Cr-EDTA clearance were used for the evaluation of the formula on the validation set and were consistent with those calculated by nonlinear regression. The 51 Cr-EDTA concentrations (cpm ml -1 ) versus time data were used directly in the population analyses.
Population pharmacokinetic analysis
Model development
The pharmacokinetics of 51 Cr-EDTA were analysed in the model development dataset (n = 62) using the first-order conditional estimation method in the computer program NONMEM V5 (Boeckmann et al, 1997 ). The data were described accurately by a one compartment model with first-order elimination. This model was parameterized in terms of clearance and volume of distribution, with an interindividual random effect on each parameter. A proportional error model best described interindividual and residual error. For interindividual error, this model is consistent with the implied loss function, as percentage errors in dose are closely related to percentage errors in AUC obtained. Although supported by the fit of the model without covariates, these assumptions were re-evaluated as the explanatory covariate model for clearance was adjusted. As over 20 covariates were available, it was necessary to take a pragmatic approach to the selection of important covariates and their relationship to each other in the formula. The inclusion of a covariate in the formula, and the appropriateness of the functional form chosen, were determined primarily by changes in residual plots, estimates of interindividual variability and the NONMEM objective function, although no statistical significance was attached to changes in the latter measure. Initial investigations were based on Efroymson's algorithm (Efroymson, 1962) , a subset selection procedure that alternates between forward selection and backward elimination, commencing from covariate models selected randomly and also those suggested from prior considerations.
Comparisons on the validation set Bias was assessed by the mean percentage error (MPE) and precision by mean absolute percentage error (MAPE). Respectively, these are calculated for n patients as:
where y is the estimate and x is the observed value. In comparing the derived and existing formulae for GFR, the statistical significance of differences in MPE and MAPE was assessed using the paired t-test and the Wilcoxon signed rank test, respectively.
RESULTS
Comparison of serum creatinine assays
Systematic differences were found between the kinetic Jaffe and enzymatic serum creatinine assays (Figure 1 ). The Jaffe method gave higher results than the enzymatic at lower concentrations (<100 micromoles l -1 ). This is consistent with endogenous interfering substances resulting in a higher value with the former assay. At higher concentrations, the enzymatic assay produced larger values than the kinetic Jaffe. As serum creatinine measures are reciprocally related to renal function, the discrepancies at the lower end of the range (high GFR) would have a large impact on GFR estimation.
Development of formulae
Given these differences between assays, independent predictive formulae were derived for each assay. The formulae derived from the initial 62 patients are shown in Table 2 , together with those for the most commonly used current methods, the Cockcroft and Gault and Jelliffe formulae. The functional form of the newly derived formulae is identical to that of the Jelliffe formula, but the coefficients differ substantially. This format for the equation was found to provide the best estimates of 51 Cr-EDTA clearance, although numerous other combinations of additive and multiplicative models were explored. Dubois Body surface area (Dubois and Dubois, 1916) The covariate creatine kinase (CK) was also found to be important in the model. Since accurate and reproducible measures of CK activity may not be universally available, formulae without this covariate were also derived. There was no detectable independent influence on EDTA clearance of prior cisplatin therapy, nephrectomy or presence of pelvic disease in the patients studied. Numbers in parentheses refer to equations in Table 2 . MAPE is mean absolute percentage error, a measure of precision, and MPE is mean percentage error, a measure of bias.
The effect of gender on GFR was relatively small (typical female GFR 77-85% that of typical male). This is similar to the arbitrary correction factor introduced by Cockcroft and Gault. With the enzymatic assay using equation (1), GFR changes by approximately 8% for 10 years of age difference from the median (57 years). Changes of BSA of 0.1 m 2 produce GFR changes of 5%. The relationship with SCr is a reciprocal one, but around the median value, an increase in GFR of 20% is associated with a decrease in SCr of 14 micromoles l -1 , while a 20% decrease corresponds to a SCr increase of 20 micromoles l -1 . Variation of CK from 22 to 114 (median 50) units l -1 is associated with a 10% variation of GFR around the median value.
Comparison of new and existing formulae
Measures of performance calculated from the separate validation set for each formula are shown in Table 3 . The derived formulae were more precise and less biased than the Cockcroft and Gault formula and it would appear that, in general, enzymatic serum creatinines gave more accurate estimates of GFR. Statistical comparisons of the estimates of GFR from each formula are shown in Table 4 . As shown in Figure 2 , the formulae derived here, for both methods of serum creatinine assay, are significantly less biased than the C&G or Jelliffe formulae. Figure 3 shows a comparison of the 51 Cr-EDTA clearance in the validation dataset, with estimates obtained either by equation 1, or using the C&G formula. The performance of the formula developed here is superior to that of C&G, with almost all of the patients estimated GFR within 20% of the observed value. While no effect of was observed in the model development group, 4 of the 5 patients (one had no enzyme creatinine measure) in the validation group who had previously been treated with cisplatin seemed to show a small but systematic bias in the estimation of GFR (Figure 3 ). In 2 of these patients EDTA clearance was overestimated by greater than 20%. This phenomenon should be investigated further and care should be taken in applying the proposed formula in cisplatin-pretreated patients.
DISCUSSION
A measure of glomerular function provides a practical, easily obtainable method to estimate overall renal function. In the treatment of patients with carboplatin, a good measure of renal function is essential to obtain predictable and uniform pharmacological exposure to active drug. The optimum method for GFR estimation, and that used to derive the Calvert equation, is clearance of 51 Cr-EDTA. Substitution of other methods for estimation of GFR has been employed, with varying degrees of success. Unfortunately, the most commonly used method, the Cockcroft and Gault equation with a measure of serum creatinine, results in significant Cr-EDTA clearance, plotted with line of identity and 20% error boundaries. Data for males (q q) and females (q) plotted separately. Triangles indicate patients with prior cisplatin treatment deviation from the target AUC. The use of the C&G model to estimate GFR is not appropriate for dosing of carboplatin because it was derived in an inappropriate patient population, takes no account of non-GFR elimination of creatinine and is highly dependent on the method used to measure creatinine in serum.
In this study the relationship between 51 Cr-EDTA pharmacokinetics and patient covariates has been explored in order to develop a more robust, flexible and reliable equation for the calculation of renal function from serum creatinine. The population pharmacokinetic approach has been applied to a number of drugs used in chemotherapy, and its use to estimate GFR from the pharmacokinetics of EDTA represents the use of contemporary analysis methods to a persistent clinically-relevant problem.
A potential source of variability in the results previously reported for GFR estimation arises from the serum creatinine assay since different methods give systematically different results (Figure 1) . Creatinine is partially eliminated by tubular secretion, in addition to glomerular filtration. The commonly used alkaline picrate colourimetric reaction (Jaffé reaction) over-estimates the serum level of creatinine by a similar proportion, thus partly compensating for the error. Thus, when a 24-hour creatinine clearance measurement is made, the potential over-estimation of GFR is compensated by the over-estimation of the serum (but not the urinary) level of creatinine. However, if one of the more accurate, enzymatic methods for creatinine measurement is used, then GFR will be overestimated. In all the formulae for GFR developed to date, the reciprocal of serum creatinine is used, thus even small discrepancies between assays can compromise GFR prediction. It would appear from this study that the enzymatic creatinine assay gave more informative serum creatinine values for the prediction of renal function, especially in conjunction with the adjustment for creatine kinase (CK).
As in previous studies, the C&G formula was found to underestimate GFR (or carboplatin clearance) on average and produced widely scattered predictions (Van Warmerdam et al, 1996; Okamoto et al, 1998; Ando et al, 1997) . Another study has shown that C&G overpredicts GFR in renally impaired patients (Levey et al, 1999) . The poor performance of C&G may be a consequence of differences between the populations under study, or of variations in the assay method for serum creatinine. Cockcroft and Gault based their formula on 249 patients, of whom only 4% were female, and excluded patients whose serum creatinine was not deemed to be at steady state. The validation set in this study indicates that the use of the C&G formula will systematically underestimate GFR in patients with normal or mildly impaired renal function. When C&G is used as the basis for carboplatin dosing it has been common for target AUCs to be set higher than when an isotope method is used (Ando et al, 1997) . Nevertheless, pharmacokinetically based dosing of carboplatin using C&G, although greatly superior to surface-area based dosing, will still lead to a wide scatter of AUC values, with patients potentially receiving either toxic or sub-therapeutic doses.
An improved formula recently proposed by Martin et al (1998) was derived in cancer patients using similar methodology to the current investigation. In that study, the statistical comparison with C&G was limited to failing to reject the null hypothesis that their formula was unbiased, a hypothesis successfully rejected for C&G. However, on the validation set in this study, the formula suggested by those authors showed no improvement in precision over C&G, due to a skewed distribution of prediction errors (data not shown).
The estimates of GFR from the Jelliffe formula were extremely downward biased in the validation set, perhaps because this formula was originally based on 15 patients who had undergone renal transplantation. Using the population pharmacokinetic approach, the formulae arrived at have the same structural form as that of Jelliffe, although the coefficients estimated from the current study are substantially different. Jelliffe assumed that the percentage reduction in GFR for female patients, all other covariates being equal, was 10%; compared to the 17% estimated in this study. C&G assumed 15% in their weight-based formula, but Martin et al estimated the value to be somewhat higher at 25%. A similar coefficient for the negative effect of age was found by Jelliffe (-41 ) and in the current study (-39) . The consistently lower predictions of the former formula are due to the difference in the constant term in the first bracket.
Recently, Levey et al derived several formulae for the estimation of renal function from 1628 patients with renal disease (Levey et al, 1999 ). This population is fundamentally different from that studied here and using their formula, also derived from readily available patient covariates, on the validation set provided predictions comparable to that of the Jelliffe formula (MAPE 20%, MPE -15%, range -50% to 31%, with the Jaffe creatinine assay; MAPE 17%, MPE-11%, range -52% to 53% with the enzymatic assay). Interestingly, their formula was derived using a kinetic alkaline picrate assay for serum creatinine. This comparison illustrates the dangers of applying formulae in populations different from that in which they were derived -not only are there difficulties in extrapolating into regions with little data, but the relationship between covariates and renal function need not be the same in different populations. Indeed, Levey et al found both serum urea nitrogen and albumin to be useful independent predictors, whereas these covariates did not appear to be predictive in the current study population.
Although Martin et al used weight rather than BSA as a measure of body size (Martin et al, 1998) , the effect of age (-0.50% GFR per year) is similar to the enzymatic formula derived here (equation 2, -0.53% per year). The use of weight was investigated, but could not be justified in this study. It is important that Dubois BSA (0.007184 × weight 0.425 × height 0.725 ) (Dubois and Dubois, 1916 ) is used, as the Gehan and George estimate of BSA (0.02350 × weight 0.51456 × height 0.42246 ) (Gehan and George, 1970) places more emphasis on weight and failed to improve predictive performance.
The use of creatine kinase (CK) in the prediction of GFR is novel. CK is released into the bloodstream by cardiovascular and skeletal muscle turnover and gross elevation of serum CK is a symptom of myocardial infarction. A source of interindividual variation in serum creatinine, other than renal function, is its rate of endogenous production. Creatine kinase was investigated as a covariate because it mediates the interconversion of creatinine and creatine intracellularly, and so may directly influence serum creatinine levels, as well as reflecting the rate of muscle turnover. Cachexia in cancer patients may cause reduced muscle mass and hence reduced creatinine production in some patients. Even in the absence of cachexia, there is likely to be interindividual variation in the rate of endogenous creatinine production, for which CK may act as a surrogate. The inclusion of CK in the formula led to significantly less bias, particularly when used in conjunction with the enzymatic creatinine assay (equation 1). Any adverse effect on GFR estimation due to artefactually elevated values of CK is minimised by the use of a logarithmic transformation. CK may prove to be a useful surrogate in other populations, however care must be taken in employing this covariate when it takes very high values.
Given that a primary aim of estimating GFR is its use in carboplatin dosing, Chatelut et al (1995) used a population pharmacokinetic approach with NONMEM to derive a formula for the dosing of carboplatin based directly on weight, age and serum creatinine. The latter was determined by the Ektachem enzymatic assay. The Chatelut formula for carboplatin clearance:
gives different results to doses predicted using the Calvert formula with 51 Cr-EDTA clearance. Compared to estimates derived from the latter method, the Chatelut formula has an MPE of 4%, an MAPE of 17% and a range of -34% to +45%. Substituting the enzymatic formulae with CK (equation 1) into the Calvert formula gives a MPE 2%, a MAPE of 9% and a range of -17% to +26%.
Studies comparing the performance of the Chatelut formula with carboplatin pharmacokinetics have shown conflicting results. Okamoto et al (1998) , studied 52 patients who had received carboplatin. Using an enzymatic assay for SCr, the Chatelut formula was inferior to dosing using C&G in the Calvert formula, especially with low doses of carboplatin. It was proposed that differences between the SCr assay or demographic differences between the patients studied may have been responsible. van Warmerdam et al (1996) studied carboplatin pharmacokinetics in 14 non-small cell lung cancer patients with metastatic or unresectable disease, who were also receiving etoposide, ifosfamide and mesna. They found similar root mean square errors for the prediction of AUC using the Chatelut formula (14%), or the Calvert formula with C&G (17%) or 24-hour creatinine clearance (15%). It was concluded that the Chatelut formula was superior, as the null hypothesis that it was unbiased (MPE = -5%) could not be rejected on this small dataset, which was not the case for 24-hour creatinine clearance (MPE = -9%) and C&G (MPE = 11%). A recent study of the combination of carboplatin, dosed according to Chatelut, in combination with irinotecan in 11 patients also found a good correlation between predicted and observed clearance (Fukuda et al, 1999) .
The study presented here extends and refines those previously performed in this area. The effects of different assay methods for serum creatinine, particularly the more common Jaffe assay, on renal function prediction have been evaluated and creatine kinase has been identified as a novel predictive factor for GFR estimation. Evaluation of the models developed in the independent validation dataset suggests that the formulae described here represent an improvement on those currently available. These formulae are not recommended for use in paediatric patients, where the dosing of carboplatin should be estimated from weight and 51 Cr-EDTA halflife (Newell et al, 1993) or from direct determination of carboplatin pharmacokinetics (Peng et al, 1995) . Nor should these formulae be used in patients with acute renal failure, as they constitute an entirely different population to that studied.
The formulae derived here provide accurate and assay-specific predictions and will permit more accurate dosing of carboplatin, via the Calvert formula, and more precise estimation of renal function in clinical investigations. Following publication of this method in abstract form (Wright et al, 1999) , a prospective evaluation (Huitema et al, 2000) has confirmed the accuracy and precision of the model. They should also be applicable to the individualised dosing of other drugs, such as aminoglycoside antibiotics, and the routine monitoring of renal function before and after potentially nephrotoxic chemotherapy.
